早期免疫重塑引导晚期胃癌一线化疗免疫治疗的临床反应
在晚期胃食管腺癌(GEA)一线II期试验(n=47)中,序贯加入帕博利珠单抗至5-氟尿嘧啶/铂类方案,对原发肿瘤进行基线和治疗中连续活检,转录组分析358,067个单细胞以识别演变的多细胞肿瘤微环境网络,发现化疗在慢进展者中诱导早期多细胞枢纽,而快速进展者呈现耐药程序和免疫抑制性间质相互作用。
要点
- 化疗在慢进展者中诱导肿瘤反应性T细胞与M1样巨噬细胞相互作用的多细胞枢纽。
- 快速进展者肿瘤细胞表达含MUC5A和MSLN的耐药程序,M2样巨噬细胞参与免疫抑制性间质相互作用。
- 帕博利珠单抗后CD8 T细胞浸润增加,形成涉及肿瘤反应性CXCL13 T细胞程序与上皮干扰素刺激基因程序的免疫枢纽。
核心结论
- 多细胞肿瘤微环境枢纽的协同诱导可提示抗PD-1增强T细胞驱动反应的能力,差异化的枢纽发展揭示了临床结局背后的特征。
研究设计与样本
- II期一线试验(n=47),在晚期胃食管腺癌中序贯将帕博利珠单抗加入5-氟尿嘧啶/铂类方案。
- 对原发肿瘤在基线、一周期5-氟尿嘧啶/铂类后及加入帕博利珠单抗后进行连续活检,转录组分析358,067个单细胞。
主要发现
- 化疗在慢进展者中诱导早期治疗中多细胞枢纽,含肿瘤反应性T细胞与M1样巨噬细胞相互作用。
- 快速进展者肿瘤细胞含MUC5A和MSLN的耐药程序增加,M2样巨噬细胞与免疫抑制性间质相互作用。
- 帕博利珠单抗后观察到CD8 T细胞浸润增加,形成涉及肿瘤反应性CXCL13 T细胞程序与上皮干扰素刺激基因程序的免疫枢纽。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Adding anti-programmed cell death protein 1 (anti-PD-1) to 5-fluorouracil (5-FU)/platinum improves survival in some advanced gastroesophageal adenocarcinomas (GEA). To understand the effects of chemotherapy and immunotherapy, we conducted a phase II first-line trial (n = 47) sequentially adding pembrolizumab to 5-FU/platinum in advanced GEA. Using serial biopsy of the primary tumor at baseline, after one cycle of 5-FU/platinum, and after the addition of pembrolizumab, we transcriptionally profiled 358,067 single cells to identify evolving multicellular tumor microenvironment (TME) networks. Chemotherapy induced early on-treatment multicellular hubs with tumor-reactive T-cell and M1-like macrophage interactions in slow progressors. Faster progression featured increased MUC5A and MSLN containing treatment resistance programs in tumor cells and M2-like macrophages with immunosuppressive stromal interactions. After pembrolizumab, we observed increased CD8 T-cell infiltration and development of an immunity hub involving tumor-reactive CXCL13 T-cell program and epithelial interferon-stimulated gene programs. Strategies to drive increases in antitumor immune hub formation could expand the portion of patients benefiting from anti-PD-1 approaches. SIGNIFICANCE: The benefit of 5-FU/platinum with anti-PD-1 in first-line advanced gastric cancer is limited to patient subgroups. Using a trial with sequential anti-PD-1, we show coordinated induction of multicellular TME hubs informs the ability of anti-PD-1 to potentiate T cell-driven responses. Differential TME hub development highlights features that underlie clinical outcomes. This article is featured in Selected Articles from This Issue, p. 695.
引用
- An M, Mehta A, Min BH, et al. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer. Cancer Discov. 2024. PMID: 38319303. doi:10.1158/2159-8290.CD-23-0857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。